65 related articles for article (PubMed ID: 21225744)
1. Anti-EMMPRIN treatment of HNSCC in an ex vivo model.
Dean N; Helman E; Aldridge J; Carroll W; Magnuson S; Rosenthal E
Laryngoscope; 2010; 120 Suppl 4():S146. PubMed ID: 21225744
[No Abstract] [Full Text] [Related]
2. Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model.
Dean NR; Knowles JA; Helman EE; Aldridge JC; Carroll WR; Magnuson JS; Clemons L; Ziober B; Rosenthal EL
Anticancer Drugs; 2010 Oct; 21(9):861-7. PubMed ID: 20700044
[TBL] [Abstract][Full Text] [Related]
3. EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts.
Newman JR; Helman EE; Safavy S; Zhang W; Rosenthal EL
Cancer Lett; 2009 Feb; 274(2):313-8. PubMed ID: 18990485
[TBL] [Abstract][Full Text] [Related]
4. EGFR codon 497 polymorphism - implications for receptor sensitivity to inhibitors in HNSCC cell lines.
Krohn V; Wiegand S; Werner JA; Mandic R
Anticancer Res; 2011 Jan; 31(1):59-65. PubMed ID: 21273581
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
Fujita K; Sano D; Kimura M; Yamashita Y; Kawakami M; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
Oncol Rep; 2007 Jul; 18(1):47-51. PubMed ID: 17549344
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy for squamous-cell carcinoma of the head and neck.
Papaspyrou G; Werner JA; Dietz A
Expert Opin Pharmacother; 2011 Feb; 12(3):397-409. PubMed ID: 21254947
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma.
Bonner JA; Yang ES; Trummell HQ; Nowsheen S; Willey CD; Raisch KP
Radiother Oncol; 2011 Jun; 99(3):339-43. PubMed ID: 21704410
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells.
Huang Z; Wang L; Wang Y; Zhuo Y; Li H; Chen J; Chen W
J Oral Pathol Med; 2013 Aug; 42(7):541-6. PubMed ID: 23413783
[TBL] [Abstract][Full Text] [Related]
11. 7beta-hydroxycholesterol induces apoptosis and regulates cyclooxygenase 2 in head and neck squamous cell carcinoma.
Heiduschka G; Erovic BM; Vormittag L; Skoda C; Martinek H; Brunner M; Ehrenberger K; Thurnher D
Arch Otolaryngol Head Neck Surg; 2009 Mar; 135(3):261-7. PubMed ID: 19289704
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effects of telomelysin for head and neck squamous cell carcinoma.
Fujita K; Kimura M; Kondo N; Sakakibara A; Sano D; Ishiguro Y; Tsukuda M
Oncol Rep; 2008 Dec; 20(6):1363-8. PubMed ID: 19020715
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
14. Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
Gilbert J; Argiris A
Clin Adv Hematol Oncol; 2006 Aug; 4(8):611-9. PubMed ID: 17099619
[TBL] [Abstract][Full Text] [Related]
15. Higher potency of the synthetic retinoid MX3350-1 compared to the natural all-trans-retinoic acid in modulation of cell cycle and induction of apoptosis in head and neck squamous carcinoma cells.
Chun KH; Lotan R
Cell Death Differ; 2006 Oct; 13(10):1830-2. PubMed ID: 16601752
[No Abstract] [Full Text] [Related]
16. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells.
Khan Z; Khan N; Tiwari RP; Patro IK; Prasad GB; Bisen PS
Radiother Oncol; 2010 Aug; 96(2):267-73. PubMed ID: 20638740
[TBL] [Abstract][Full Text] [Related]
18. Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.
Abrahão AC; Giudice FS; Sperandio FF; Pinto Junior Ddos S
J Oral Pathol Med; 2013 Nov; 42(10):793-8. PubMed ID: 23679684
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
[TBL] [Abstract][Full Text] [Related]
20. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
